Company or ticker...

COMPASS Pathways

COMPASS develops psilocybin-based mental health treatments, mainly for treatment-resistant depression.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

CMPS

1.8B

0.0

n/a

90.43%

Key Facts

M. Cap

PS

PE

YTD

1.8B

0.0

n/a

90.43%

10MA

20MA

50MA

200MA

$CMPS